Protalix BioTherapeutics PLX
NYSE PLX
$3.13 +0.28 (+9.62%)
As of: Nov 11, 2026 · 3:59 PM EST

Protalix BioTherapeutics (PLX) Research & Development (2009 - 2026)

Updated

Protalix BioTherapeutics (PLX) posted Research & Development of $4.35 million for Q2 2026, down 27.4% from $5.99 million a year earlier and down 19.8% from the prior quarter.

Analysis

Protalix BioTherapeutics (PLX) Research & Development (2009 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Research & Development at Protalix BioTherapeutics was $19.88 million, up 19.8% year-over-year; for FY2025, it was $19.57 million, up 50.9% from FY2024.

  • Annual Research & Development shows a five-year compound annual growth rate of -12.5% (FY2020 to FY2025).
  • In prior years, Protalix BioTherapeutics' Research & Development was $12.97 million in FY2024 (-24.1%), $17.09 million in FY2023 (-41.8%), $29.35 million in FY2022 (-1.3%) and $29.73 million in FY2021 (-22.1%).
  • The Q2 2026 figure stands as the lowest quarterly Research & Development since Q1 2025.
  • On a year-over-year basis, Research & Development increased in six of the last eight quarters, with growth averaging 31.5%.
  • The strongest year-over-year quarter for Research & Development in the past five years was Q2 2025, with growth of 102.4%; the weakest was Q1 2024, with a decline of 50.6%.
  • According to Business Quant data, Research & Development for the three prior quarters was $5.43 million (Q1 2026), $5.64 million (Q4 2025) and $4.47 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 4.25 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 4.65 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.57 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.54 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 3.89 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 2.11 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 1.61 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 3.02 Bn
10 Protalix BioTherapeutics 230.43 Mn 59.88 Mn 14.05 Mn 6.92 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 6.92 Mn
Jun 30, 2026 4.35 Mn
Mar 31, 2026 5.43 Mn
Dec 31, 2025 5.64 Mn
Sep 30, 2025 4.47 Mn
Jun 30, 2025 5.99 Mn
Mar 31, 2025 3.48 Mn
Dec 31, 2024 4.12 Mn
Sep 30, 2024 3.00 Mn
Jun 30, 2024 2.96 Mn
Mar 31, 2024 2.89 Mn
Dec 31, 2023 3.10 Mn
Sep 30, 2023 3.67 Mn
Jun 30, 2023 4.48 Mn
Mar 31, 2023 5.85 Mn
Dec 31, 2022 5.62 Mn
Sep 30, 2022 7.39 Mn
Jun 30, 2022 7.58 Mn
Mar 31, 2022 8.77 Mn
Dec 31, 2021 7.64 Mn
API Access

Protalix BioTherapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=PLX&period=max&api_key=YOUR_API_KEY